NEI Podcast

Neuroscience Education Institute

Neuroscience Education Institute (NEI)

All Episodes

What was the inspiration behind creating the Fifth Edition video series? What are your best learning strategies for studying psychopharmacology? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the Fifth Edition Video Series and about the most effective learning strategies for psychopharmacology! With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology? Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology Part 3: The Future of Psychopharmacology Subscribe to the NEI Podcast, so that you don’t miss another episode!

Nov 17

35 min 53 sec

In this episode, Dr. Jeffrey Strawn addresses your unanswered questions from his presentation: Re-Counting Neurobiological Treatment Advances of Obsessive-Compulsive Disorder.    Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents.In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders. 

Nov 9

11 min 14 sec

In this episode, Dr. Manpreet Singh answers your unaddressed questions from her presentation: It's a Woman's World: Exploring Female Mental Health Issues at the 2021 NEI Congress.    Dr. Manpreet K. Singh is Associate Professor of Psychiatry and Behavioral Sciences, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders.Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009.   Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes.

Nov 7

19 min 18 sec

In this episode, Dr. Napoleon Higgins and Dr. Rona Hu address your most pressing questions from their presentation on cultural humility at the 2021 NEI Congress.    Dr. Napoleon Higgins is a child, adolescent and adult psychiatrist in Houston, Texas. He is the owner of Bay Pointe Behavioral Health Services and South East Houston Research Group. He is the President of the Black Psychiatrists of Greater Houston, Past President of the Caucus of Black Psychiatrists of the American Psychiatric Association and Past President of the Black Psychiatrists of America, Inc.Dr. Higgins is co-author of How Amari Learned to Love School Again: A Story about ADHD, Mind Matters: A Resource Guide to Psychiatry for Black Communities and author of Transition 2 Practice: 21 Things Every Doctor Must Know in Contract Negotiations and the Job Search. He also specializes in nutrition and health to improve patients’ lives mentally and physically. He emphasizes that good mental and physical health are key in the practice of psychiatry and medicine.   Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the University of California, San Francisco Medical Center in 1994. She received her board certification in psychiatry in 1995 from the American Board of Psychiatry and Neurology.Dr. Hu completed two fellowships while at the National Institutes of Health (NIH) from 1994-1998. She completed the PRAT (Pharmacology Research Associate Training) program from 1994-1996, and a schizophrenia research fellowship from 1996-1998. Dr. Hu received the 2016 APA Nancy Roeske award for Excellence in Medical Student Education, the 2017 Faculty Award from Stanford University's Asian American Activities Center, and the 2017 Community Engagement Award from Stanford Department of Psychiatry.

Nov 7

25 min 19 sec

In this episode, Dr. Charles Scott addresses some of your unanswered questions from his presentation on cannabis and violence.    Dr. Scott is Chief, Division of Psychiatry and the Law, Forensic Psychiatry Fellowship Training Director, and Professor of Clinical Psychiatry at the University of California, Davis Medical Center in Sacramento, California. He is Board Certified in Forensic Psychiatry, General Psychiatry, Child and Adolescent Psychiatry, and Addiction Psychiatry. Dr. Scott has served as a forensic psychiatric consultant to jails, prisons, maximum security forensic inpatient units, California Department of State Hospitals, and as a consultant to the National Football League (NFL) providing training on violence risk assessment for NFL counselors.   His research interests include the relationship of substance use to aggression among criminal defendants, on the quality of forensic evaluations of criminal responsibility, child witness testimony, malingering, and assessment of posttraumatic stress disorder. He lectures nationally on the topics of malingering, violence risk assessment, juvenile violence, substance use and violence, the assessment of sex offenders, correctional psychiatry, DSM-5 and the law, and malpractice issues in mental health.

Nov 5

16 min 21 sec

What are you most excited about, when it comes to this year’s NEI Congress? What is one benefit that both live and virtual attendees will experience at the 2021 NEI Congress? In this episode, we get a sneak peek at what to expect from this highly anticipated event! With the live and virtual simulcast formats, there are a lot of questions and A LOT of excitement! Whether you’ll be joining us in beautiful Colorado Springs or from the comfort of your own home, we have an unforgettable experience planned for you! Listen to this episode to learn more about what’s to come at the 2021 NEI Congress!  

Nov 3

16 min 26 sec

In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre on best practices for using adjunctive treatment for major depressive disorder. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MDD Learning Objectives: After completing this educational activity, you should be better able to: Discuss earlier identification of partial response to anti-depressants and advantages to implementing augmentation strategies sooner to improve treatment outcomes Increase awareness about evidence-based adjunctive treatments that are FDA-approved for depression Examine the pharmacological profiles of approved adjunctive atypical antipsychotic treatments in terms of how they relate to therapeutic benefits and adverse reactions Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this online live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME/CE Credit Types. The following are being offered for this activity: Nursing (ANCC): 1.0 contact hour Pharmacy (ACPE): 1.0 application-based contact hour Physician (ACCME): 1.0 AMA PRA Category 1 Credit ™ Physician Assistant (AAPA): 1.0 Category 1 CME credit Psychology (APA): 1.0 CE credit Social Work (ASWB-ACE): 1.0 ACE CE credit Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for 1.0 AMA PRA Category 1 Credit ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/National Natural Science Foundation of China Consultant/Advisor: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda Speakers Bureau: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck. Released: October 21, 2021          CE credit expires: October 21, 2024    

Oct 28

1 hr 1 min

What are some of the biggest changes that were made to the Fifth Edition and what were the reasons behind these changes? How are mood stabilizers redefined in the Fifth Edition? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about all the updates to the Fifth Edition of Stahl’s Essential Psychopharmacology and all the exciting reasons for those updates. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology? Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology Part 3: The Future of Psychopharmacology Subscribe to the NEI Podcast, so that you don’t miss another episode!

Oct 20

49 min 18 sec

What is unique about collaborative care, when it comes to mental health? Can you share some of the step-by -step guide to implementing the core model in clinical practice for collaborative care? In this episode, Dr. Anna Ratzliff answers these questions and much more! Dr. Anna Ratzliff is a national expert on collaborative care and specifically, on training teams to implement and deliver mental health treatment in primary care settings. Her passion for translating complex research ideas into practical real-world applications began when she received her MD and PhD in Anatomy and Neurobiology as part of the Medical Scientist Training Program at the University of California at Irvine.  She currently is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington where she has developed additional expertise in suicide prevention training, mental health workforce development, adult learning best practices, and mentorship. Dr. Ratzliff is the Director of the UW Psychiatry Resident Training Program, Co-Director of the AIMS Center (Advancing Integrated Mental Health Solutions) and Director of the UW Integrated Care Training Program for residents and fellows. Resources: AIMS Center Website: http://aims.uw.edu/ Implementation Guide: https://aims.uw.edu/collaborative-care/implementation-guide APA Training: https://www.psychiatry.org/psychiatrists/practice/professional-interests/integrated-care

Oct 6

36 min 29 sec

In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer on best practices and strategies for improving clinician and patient communication, medication adherence, and collaboration in the community when it comes to treating schizophrenia. Optional CE Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click https://nei.global/POD21-Schiz Learning Objectives: After completing this educational activity, you should be better able to: Demonstrate strategies that involve patient and caregivers in shared informed decision-making for treatment goals Discuss the role of social aspects of community and behavioral health settings on patient experiences and treatment outcomes Address best practices for the use of telemedicine when monitoring treatment for schizophrenia and the use of LAIs Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.25 continuing education hours of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Intra-Cellular, Neurocrine Speakers Bureau: Acadia, Alkermes, Intra-Cellular, Neurocrine, Noven, Otsuka, Sunovion, Teva Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck. Released: September 23, 2021          CE credit expires: September 23, 2024

Sep 23

1 hr 1 min

Why do you feel that when it comes to psychopharmacology, knowing how to really interpret the scientific literature is important for clinicians? Why is it important to know whether the clinical characteristics of the subjects resemble or differ from your own patients and to what extent?  In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn more about why it is important to understand how to interpret the scientific literature and apply it to your clinical practice. Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg   https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

Sep 16

50 min 35 sec

What are the most critical components that need to be addressed about social wellbeing when it comes to children returning to school? What signs might alert parents to their children feeling anxious about returning to school? In this timely and important interview. Dr. Manpreet Singh and Dr. Jeffrey Strawn answer these questions and much more! To access the article that Dr. Singh refers to in this episode click here: https://www.nytimes.com/2021/08/20/well/family/back-to-school-fear-tip.html Dr. Manpreet K. Singh is Associate Professor of Psychiatry and Behavioral Sciences, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders. Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes. Dr. Jeffrey Strawn is Associate Professor in the Department of Pediatrics and in the Department of Psychiatry and Behavior Science at the University of Cincinnati, College of Medicine in Cincinnati, OH. Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents.  In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders.

Sep 1

32 min 33 sec

What is the difference between mediators and moderators, and how do they influence treatment response? Why is it so important, as clinicians to understand the distinction between moderators and mediators and to be aware of their influence on treatment outcomes in the literature?  In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn more about how moderators and mediators influence clinical outcomes. Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg    https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

Aug 18

56 min 8 sec

Why is it so important that many Olympic athletes are speaking out about the importance of mental health, and how can people spread more awareness for mental health concerns in this vulnerable population? What challenges do you face regarding effectively treating mental health conditions in athletes? In this important and timely interview sports psychiatrist, Dr. Greg Mattingly addresses these questions and much more! Dr. Mattingly is a physician and principal investigator in clinical trials for Midwest Research Group. He is also a founding partner of St. Charles Psychiatric Associates where he treats children, adolescents and adults. A St Louis native, he earned his medical degree and received a Fulbright scholarship while attending Washington University. Dr. Mattingly is board certified in adult and adolescent psychiatry and is a Diplomat of the National Board of Medical Examiners. He is an Associate Clinical Professor at Washington University. Dr. Mattingly has been a principal investigator in over 300 clinical trials focusing on ADHD, anxiety disorders, major depression, bipolar disorder and schizophrenia. Having served on numerous national and international advisory panels, Dr. Mattingly has received awards and distinctions for clinical leadership and neuroscience research. Dr. Mattingly currently serves on the board of directors for APSARD-The American Professional Society of ADHD and Related Disorders and is a certified evaluator for both the NFL and MLB. An avid runner and outdoorsman, Dr. Mattingly believes mind, body and spirit are important qualities for him and his family. Resources: www.Midwestresearchgroup.com

Aug 4

18 min 49 sec

In this episode, Dr. Andrew Cutler interviews Dr. Leslie Citrome on some of the challenges that clinicians face when using traditional methods for the treatment of schizophrenia. They discuss the most current research on the development of TAAR1 agonists as a novel class of psychotropic medication for the treatment of schizophrenia. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD21-TAAR1  Learning Objectives: After completing this educational activity, you should be better able to: Describe the challenges with traditional methods of treating schizophrenia Discuss the development of TAAR1 agonists as new class of psychotropic medication for the treatment of schizophrenia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Astellas, Avanir, Axsome, BioXcel, Cadent Therapeutics, Eisai, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Relmada, Sage, Shire, Sunovion, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sage, Shire, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Sunovion Pharmaceuticals Inc. Released: July 29, 2021 CME credit expires: July 29, 2024

Jul 29

45 min 3 sec

How do you handle a patient who doesn’t want to talk about their suicidal thoughts? What tools and basic education strategies can we use for non-health-care professionals to highlight and prevent potential suicide/suicidal thoughts?  In this episode, Dr. Christine Moutier addressed your unanswered questions from the NEI Synapse Half Day: Before It’s Too Late: Strategies for Suicide Prevention. Dr. Moutier is the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP).  Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions. As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide. Moutier has authored Suicide Prevention, a Stahl's series handbook, articles and book chapters for publications such as the Journal of the American Medical Association, the Lancet, Academic Medicine, the American Journal of Psychiatry, the Journal of Clinical Psychiatry, Depression and Anxiety, and Academic Psychiatry. She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN, and other print and television outlets. You can follow Dr. Moutier on Twitter at @cmoutierMD. For more information on the AFSP please visit: asfp.org

Jul 28

40 min 51 sec

How does the therapeutic alliance influence treatment outcomes when it comes to treatment with placebo? What are some of the other patient characteristics that influence placebo responsivity? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn about why understanding more about placebo and nocebo effects is so important for your practice. Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg    https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

Jul 21

47 min 21 sec

What are the most common mistakes in psychopharmacology, where clinicians could benefit from improvement in these areas? What are some ways in which clinicians can avoid malpractice lawsuits? In this podcast episode, Dr. Thomas Schwartz discusses the biggest mistakes that can be made in psychopharmacology, as well as best practices for clinicians to avoid malpractice in psychiatry. You won’t want to miss this episode! Dr. Thomas L. Schwartz is a professor and the Interim Chair for the Department of Psychiatry and Behavioral Sciences, and Senior Associate Dean for Education at SUNY Upstate Medical University, Syracuse, NY. He is active on many teaching, administrative and curriculum committees at SUNY, he also provides direct resident supervision, lectures in several courses, and directs and organizes continuing medical education events for the psychiatry department. Dr. Schwartz received his medical degree from and completed his residency in adult psychiatry at the State University of New York (SUNY) Upstate Medical University in Syracuse, New York. Dr. Schwartz’s abilities as a medical educator have been recognized with the Marc H. Hollander, MD, Psychiatry Award, Teacher of the Year, and Mentor of the Year awards from SUNY Upstate Medical University; Nancy Roeske, MD, Irma Bland, Certificates of Recognition for Excellence in Medical Student and Resident Education from the American Psychiatric Association, the SUNY Upstate President’s and the SUNY Chancellor’s Award for Teaching. Dr. Schwartz is the author of Practical Psychopharmacology: Basic to Advanced Principles, "Stahl’s Essential Psychopharmacology” Case Studies Volume 2, Integrating Psychotherapy and Pharmacotherapy, Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention, Second and Third Generation Antipsychotics. He is the editor of Depression: Treatment Strategies and Management, 1st and 2nd Eds. and is the Deputy Editor for the journal CNS Spectrums.

Jul 7

23 min 54 sec

What do we know about the world suicide rate and the national suicide rate? What are the differences and how might they be explained? How does the role of medications help or hinder suicide prevention? In this episode, Dr. Andrew Cutler interviews Dr. Christine Moutier and Dr. Stephen Stahl on their Suicide Prevention Handbook, where they address timely questions like these and so much more. Dr. Moutier is the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP).  Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions. As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide. Moutier has authored Suicide Prevention, a Stahl's series handbook, articles and book chapters for publications such as the Journal of the American Medical Association, the Lancet, Academic Medicine, the American Journal of Psychiatry, the Journal of Clinical Psychiatry, Depression and Anxiety, and Academic Psychiatry. She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN, and other print and television outlets. You can follow Dr. Moutier on Twitter at @cmoutierMD. For more information on the AFSP please visit: asfp.org With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention. Episodes to be released under this theme include: Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier Subscribe to the NEI Podcast, so that you don’t miss another episode!

Jun 16

52 min 52 sec

What are the positive and negative consequences surrounding self-diagnosis programs for mental health? What can you say about the trend on TikTok to take L-tyrosine? It’s apparently been nicknamed the “natural Adderall”. What is wrong with this, or potentially dangerous about this? In this episode, Dr. Kojo Sarfo, discusses the positive and negative consequences of the mental health trends on TikTok and social media. Dr. Kojo Sarfo, DNP, PMHNP-BC is a Ghanaian-American Psychiatric-Mental Health Nurse Practitioner, entrepreneur, and writer. He graduated from The University of West Alabama with his Associate’s Degree in Nursing and then obtained his Bachelor’s in Nursing from Western Governors University. He went on to obtain his Doctorate in Nursing Practice degree from Augusta University with a specialty in Psychiatry. Dr. Sarfo is dedicated to increasing awareness about mental health conditions and reducing the stigma that surrounds mental health on social media platforms, such as TikTok. His mission has been received with growing popularity, particularly in the adolescent/youth community- as he has over one million followers on TikTok. He has three years of teaching experience as an adjunct faculty professor with the College of Nursing at his alma mater, Augusta University. He has a passion for treating and caring for persons with severe mental health conditions. He is also the CEO and Co-Founder of Abrantie & Signora, LLC, which is a clothing company dedicated to spreading positivity and mental health awareness for teenagers and college students. For more information on Dr. Sarfo: https://www.kojosarfo.com/ Dr. Sarfo’s Podcast: https://podcasts.apple.com/us/podcast/the-kojo-sarfo-podcast/id1477749374 Dr. Sarfo’s YouTube Channel: https://www.youtube.com/kojosarfo Dr. Sarfo’s Clothing Company: https://abrantiesignora.com/ Dr. Sarfo’s Book: https://www.amazon.com/You-Already-Won-Education-Awareness/dp/1692141805/ref=sr_1_1?dchild=1&keywords=dr.+kojo+sarfo&qid=1603218480&sr=8-1

Jun 2

39 min 32 sec

What are the most frequent comorbidities of schizophrenia? Is there any scientific reason to use any antipsychotic in twice-a-day dosing? In this episode, Dr. Leslie Citrome addresses these questions and more of your unanswered questions from the NEI Synapse Half-Day on Novel Strategies to Treat Schizophrenia in this special NEI Podcast Bonus episode! Dr. Leslie Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. He is the Editor-in-Chief of the International Journal of Clinical Practice, published by Wiley. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and after nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and interpretation. Dr. Citrome is a member of the Board of Directors of the American Society of Clinical Psychopharmacology. Main areas of interest include schizophrenia, bipolar disorder and major depressive disorder. He is a frequent lecturer on the quantitative assessment of clinical trial results using the evidence-based medicine metrics of number needed to treat and number needed to harm. Dr. Citrome is the author or co-author of over 400 research reports, reviews, and chapters in the scientific literature, is on the editorial board of 13 different medical journals, reviews for over 90 journals, and has lectured extensively throughout the USA, Canada, Europe, and Asia.

May 26

17 min

What unique risk factors surround the COVID-19 pandemic and potential heightened risk of suicide? What populations have been most vulnerable to mental health consequences, substance use disorders, suicidal ideation, and self-harm during the pandemic and why? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on the suicide risk and prevalence during this challenging time. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention. Episodes to be released under this theme include: Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier Subscribe to the NEI Podcast, so that you don’t miss another episode!

May 19

47 min 3 sec

What are some mental health challenges for Asian Americans today? Can you share your thoughts on the most recent acts of violence against Asian Americans and where it comes from? In this timely and important episode, we interview Dr. Rona Hu on mental health in the Asian American community. Dr. Hu is Medical Director of the Acute Psychiatric Inpatient Unit at Stanford Hospital, specializing in the care of those with serious mental illnesses, including schizophrenia, bipolar and depression. She completed medical school and residency in psychiatry at the University of California, San Francisco, and fellowships in Pharmacology and Schizophrenia Research through the National Institutes of Health. She is also active in  minority issues and cultural psychiatry, and has received regional and national recognition for her clinical care, research and teaching. Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the University of California, San Francisco Medical Center in 1994. She received her board certification in psychiatry in 1995 from the American Board of Psychiatry and Neurology. Dr. Hu completed two fellowships while at the National Institutes of Health (NIH) from 1994-1998. She completed the PRAT (Pharmacology Research Associate Training) program from 1994-1996, and a schizophrenia research fellowship from 1996-1998. Dr. Hu received the 2016 APA Nancy Roeske award for Excellence in Medical Student Education, the 2017 Faculty Award from Stanford University's Asian American Activities Center, and the 2017 Community Engagement Award from Stanford Department of Psychiatry.

May 5

47 min 54 sec

What is the evidence that obesity leaves one vulnerable to bipolar disorder? Which of your patients with bipolar disorder would you refer for TMS and what has been the outcome in your experience? Have you seen development of mania with this treatment? What impact or changes have you seen in your bipolar patients who have suffered with COVID? In this Bonus episode of the NEI Podcast, Dr. Roger McIntyre addresses these questions and more unanswered questions from the Q&A session for our NEI Synapse Half-Day on The Cutting-Edge of Mood Disorders. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders. To register for Synapse Half-Days go to: https://www.neiglobal.com/Synapse/SynOverview/tabid/468/Default.aspx

Apr 28

55 min 41 sec

What do clinicians need to know about the pharmacokinetics of ketamine, especially when it comes to drug-drug interactions? What is the abuse potential for ketamine and for esketamine? What are some ways that clinicians can mitigate the risk of abuse? At this time, what is the consensus, in comparing the efficacy of ketamine and esketamine for treatment resistant depression? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on their recent publication in the American Journal of Psychiatry. To access the article click on the link: https://pubmed.ncbi.nlm.nih.gov/33726522/ Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention. Episodes to be released under this theme include: Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier Subscribe to the NEI Podcast, so that you don’t miss another episode!

Apr 21

59 min 18 sec

What has the research shown in terms of the relationship between THC and sleep and nightmares in patients with PTSD? What are your thoughts on the recent study by LaFrance et al. that claimed that PTSD symptoms were reduced by more than 50% after cannabis use? In this fascinating interview with Dr. Kari Franson, we discuss the evidence for and against the use of cannabis to treat PTSD. Kari L. Franson PharmD, PhD, BCPP joined the University of Southern California in 2020 as the Associate Dean for Academic and Student Affairs and Professor of Clinical Pharmacy. Dr. Franson received her Doctor of Pharmacy from the University of California, San Francisco, trained at the University of Illinois, Chicago Hospital and Clinics as a resident in adult internal medicine and a fellow in clinical research/drug development, and received her PhD in Medical Education from Leiden University, the Netherlands. Dr. Franson is an educator with more than 25 years of experience. Throughout her career, she has focused on two areas: health professions education/workforce development and psychopharmacology. She is an international leader in interprofessional practice, education and advocacy and workforce development to address health disparities in both the US and abroad. Dr. Franson has experience in campus and distance-based curriculum development and assessment, technology-enhanced assessment/learning, experiential education, and continuing professional education and development. Dr. Franson is also a US Board-Certified Psychiatric Pharmacist and Dutch-Certified Clinical Pharmacologist. She worked with geriatric psychiatric patients for 10 years and has performed a variety of clinical studies spanning those in early-phase clinical pharmacology to post-marketing clinical efficacy studies. She is interested in cannabinoid clinical pharmacologic effects and cannabis user safety. She has guided national and international professional, legislative, media and commercial groups on the wise study and use of cannabis.  

Apr 7

30 min 21 sec

What exactly is reconsolidation? How does disrupting this process work to neutralize fear conditioning? How has hallucinogen-assisted psychotherapy been implemented as an attempt to block reconsolidation of activated memories during psychotherapy sessions In this episode, as part of our special series, the PsychopharmaStahlogy Show, Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more! Don’t miss Part 3 of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include: Part 1: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy Part 2: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process Part 3: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories Subscribe to the NEI Podcast, so that you don’t miss another episode!

Mar 17

44 min 38 sec

What are the risk factors for pediatric anxiety, and how might those be altered by the pandemic? How can emotional intelligence and emotion regulation play a role in managing anxiety? What is self-efficacy, and why is it so important for managing pediatric anxiety? In this timely episode, we discuss how to manage pediatric anxiety with Dr. Krystal Lewis. Dr. Lewis is clinical psychologist with the Section on Development and Affective Neuroscience (SDAN) at the National Institute of Mental Health (NIMH). She is also a member of the Stigma Scientific Interest Group (SIG), and the NIMH Anti-Racism Task Force at the National Institute of Health (NIH). She specializes in cognitive behavioral therapy (CBT) for treating pediatric anxiety, and her research has focused on identifying mechanisms underlying the effectiveness of CBT. Dr. Lewis has extensive clinical experience treating anxious children and adolescents. She is also an advocate for early intervention, prevention and evidence-based treatments. She is currently a member of the Board for the Anxiety and Depression Association of America and co-chairs the Child and Adolescent Anxiety Special Interest Group. Resources Research Involvement at the NIMH: www.nimh.nih.gov/research Clinical Studies at the NIMH: clinicalstudies.info.nih.gov Clinical Study on Pediatric Anxiety: https://www.nimh.nih.gov/research/research-conducted-at-nimh/join-a-study/trials/childrens-studies/pediatric-mood-and-anxiety-research.shtml Call: (301) 827-1340 /Email: kidswithworries@mail.nih.gov Websites My Mental Health: Do I Need Help? (NIMH) 5 Things You Should Know About Stress (NIMH) COVID-19: Stress and Coping (CDC) Anxiety and Depression Association of America: https://adaa.org/ Books for children/adolescents Outsmarting Worry: The Older Kids’ Guide to Managing Anxiety: https://www.amazon.com/Outsmarting-Worry-Older-Managing-Anxiety/dp/1785927825/ref=sr_1_1?dchild=1&keywords=outsmarting+worry&qid=1613673934&s=books&sr=1-1 Rewire Your Anxious Brain For Teens: https://www.amazon.com/Rewire-Your-Anxious-Brain-Teens/dp/1684033764/ref=sr_1_3?dchild=1&keywords=rewire+your+anxious+brain+for+teens&qid=1613674062&s=books&sr=1-3 https://www.amazon.com/Teen-Girls-Anxiety-Survival-Guide/dp/1684035848/ref=sr_1_3?dchild=1&keywords=the+teens+girls+anxiety+survival+guide&qid=1613677471&s=books&sr=1-3#customerReviews Books for Parents : https://www.amazon.com/Helping-Anxious-Child-Step-Step/dp/1572245751/ref=sr_1_1?dchild=1&keywords=helping+your+anxious+child&qid=1613674245&s=books&sr=1-1 https://www.amazon.com/You-Your-Anxious-Child-Worries/dp/1583334955/ref=sr_1_1?dchild=1&keywords=anne+marie+albano&qid=1613677395&s=books&sr=1-1 https://www.amazon.com/Anxious-Kids-Parents-Courageous-Independent/dp/0757317626/ref=sr_1_3?crid=VR7NZWB285S2&dchild=1&keywords=anxious+parents+anxious+kids&qid=1613677372&s=books&sprefix=anxious+parents+%2Cstripbooks%2C167&sr=1-3

Mar 3

25 min 23 sec

What has research shown about the effectiveness of psychedelic or dissociative agents in the treatment of addiction? What is pharmacological extinction? What types of addictions have been researched, using this method as a treatment approach? In Part II of this special series, the PsychopharmaStahlogy Show Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more! Don’t miss Part III of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include: Part I: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy Part II: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process Part III: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories Subscribe to the NEI Podcast, so that you don’t miss another episode!

Feb 17

44 min 57 sec

What are the greatest mental health disparities in this population? What has been particularly challenging for the transgender population during the COVID-19 pandemic? How can clinicians help recognize and treat the mental health needs of patients in the LGBTQ community, if they do not have advanced or specialized training for this population? In this double-interview we had the opportunity to sit down with two experts who address these questions, and so much more! Dr. Rhonda Schwindt is an Associate Professor and Director of the Psychiatric-Mental Health Nurse Practitioner Program at The George Washington University School of Nursing. She is a nationally certified Psychiatric-Mental Health Nurse Practitioner with an active clinical practice specializing in LBGTQ health, trauma, and treatment-resistant psychiatric illnesses. Dr. Schwindt’s research is focused on reducing the disproportionate impact of substance use disorders among high risk populations. She has developed an innovative online module that prepares clinicians to engage in motivational interviewing and a web-based tool to assist busy clinicians with screening and brief intervention. Dr. Schwindt is currently conducting a study exploring the barriers to, and facilitators of, smoking cessation and treatment utilization among gender diverse people. She has received international recognition as an outstanding nurse educator as well as for clinical excellence in the care of persons living with mental illness.  Dr. Stephen Forssell is the founder, director, and professor of the LGBT Health Policy & Practice Graduate Certificate Program at the George Washington University. In addition, he has been an assistant professor in the Psychological and Brain Sciences Department at the George Washington University since 2002 where he teaches courses in sexuality and gender, health psychology, and social psychology. He is on the faculty of the GWU Medical Center School of Medicine and Health Sciences course in Human Sexuality and Clinical Medicine. Dr. Forssell’s expertise is in sexual orientation development, same-sex romantic relationships and parenting, HIV/AIDS risk behaviors, high risk sexual behavior interventions, adolescent and young adult romantic and sexual relationships, and health psychology. Dr. Forssell also designs program evaluations for the Human Services Administration, the Substance Abuse and Mental Health Services Administration, and for private agencies including the National Minority AIDS Council and the AIDS Alliance.  Resources: LGBT Health Policy & Practice Graduate Certificate Program at the George Washington University: https://lgbt.columbian.gwu.edu/ National LGBTQIA Health Education Center:  https://www.lgbtqiahealtheducation.org/ Human Rights Campaign: https://www.hrc.org/

Feb 3

40 min 5 sec

What types of psychotherapies are typically used in conjunction with these dissociative agents? How does psilocybin differ from ketamine for the treatment of mental health conditions? What are the risks, if any associated with this type of therapeutic approach? In Part I of this special series, the PsychopharmaStahlogy Show Dr. Andrew Cutler asks Dr. Stephen Stahl these questions, and so much more! Don’t miss Part II and Part III of this interview.  With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The first theme is on psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders. Episodes to be released under this theme include: Part I: Now You See It, Now You Don’t: The Power of Psychedelic-Assisted Psychotherapy Part II: Forgetting to Be Addicted: Altering Compulsivity in the Addiction Process Part III: Forgetting Your PTSD: Using Reconsolidation to Forget Traumatic Memories Subscribe to the NEI Podcast, so that you don’t miss another episode!

Jan 20

44 min 15 sec

In this excerpt, taken from his  presentation on the mental health consequences of COVID-19 for 2020NEIMax!, Dr. Sauve' addresses the rise in substance use disorders, and domestic violence as a result of the 2020 pandemic.  Dr. William M. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency in adult psychiatry at the National Capitol Consortium in Washington, DC, prior to deploying to the Al Anbar Province, Iraq, as the Regimental Psychiatrist for the 7th Marines. After eleven years of active duty service, Dr. Sauvé left the United States Navy to become the Clinical Director of the Military Program at Poplar Springs Hospital in Petersburg, VA, an inpatient structured program for the treatment of Posttraumatic Stress Disorder and Chemical Dependency that caters exclusively to the military population. In 2014, he left Poplar Springs Hospital to focus on Transcranial Magnetic Stimulation and now serves as the Regional Medical Director, Virginia; Greenbrook TMS NeuroHealth Centers and the Medical Director for TMS NeuroHealth Centers in Richmond (Glen Allen) and Charlottesville, VA. Dr. Sauvé also consults for pharmaceutical companies and associated industries as well. He is a member of the American Psychiatric Association, and certified by the American Board of Psychiatry and Neurology. Dr. Sauvé also recently co-authored “Psychopharmacological Treatment,” with Dr. Stahl, a chapter in Treating PTSD in Military Personnel, edited by Bret Moore and Walter Penk.

Jan 6

1 hr 1 min

We know that the COVID-19 pandemic has had a significant impact on mental health around the world. Can you share some findings with us on the effect of COVID-19 on mood disorders from the CLIMB study that was conducted this year? What were some of the new FDA approvals for medications that happened this year? In this episode, Dr, Cutler addresses these questions and so much more, as we take a look back at this year in psychopharmacology. Dr. Andrew J. Cutler is Chief Medical Officer at the Neuroscience Education Institute, and Clinical Professor in the Department of Psychiatry at SUNY Upstate Medical University, Syracuse, NY Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials. He has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings. He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards. He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations. He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences. Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society and the American Medical Association. He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media.  

Dec 2020

44 min 54 sec

Neurodegenerative disorders have become increasingly prevalent today and can often be accompanied by dementia and other neuropsychiatric conditions such as psychosis. It is important to be able to differentiate psychosis that is associated with various types of dementia, while this can be challenging to clinicians. However, there are several existing and novel therapeutics that can manage dementia-related psychosis. In this episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo on the practical strategies for the management of dementia-related psychosis. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-DemPsychosis Learning Objectives: After completing this educational activity, you should be better able to: Describe the clinical presentation of psychosis in dementia Employ pharmacological treatment strategies to ameliorate psychosis in patients with dementia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by a PhD specializing in neurodegenerative diseases to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Laxman Bhagwan Bahroo, DO Associate Professor and Residency Program Director, Department of Neurology; Director, Botulinum Toxin Clinic; MedStar Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC Consultant/Advisor: AbbVie, Acadia, Acorda, Allergan, Amneal, Neurocrine, Revance, Sunovion, US World Meds Speakers Bureau: AbbVie, Acadia, Acorda, Adamas, Allergan, Amneal, Ipsen, Neurocrine, Sunovion, UCB, US World Meds Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Acadia Pharmaceuticals. Released: December 14, 2020     CME credit expires: December 14, 2023

Dec 2020

38 min 38 sec

Despite increasing evidence that bipolar disorders often emerge in adolescence, only about half of adolescents with a bipolar disorder receive mental health care. Research has shown that an early onset of a bipolar disorder, concomitant with a poor diagnosis and lack of treatment, can have lifelong devastating effects for the patient. Adults and younger people who initially exhibit symptoms only of depression may later develop bipolar disorder. The risk of depression turning into bipolar disorder is estimated at 10 percent or less in adults but appears to be as high as 20–40 percent in children and adolescents. In this episode, Dr. Neera Ghaziuddin answers many questions regarding how to better diagnosis and treat pediatric bipolar disorder, and depression with mixed features in the pediatric population. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-PedBip Learning Objectives: After completing this educational activity, you should be better able to: Discuss challenges to diagnosing bipolar disorder in the pediatric population (e.g. adolescents) Define the concept of “mixed features” according to different diagnostic criteria Improve the differential diagnosis of depression with mixed features (DMX) in children and adolescents Utilize evidence-based therapies in the treatment of pediatric patients presenting with DMX Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in pediatric psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Neera Ghaziuddin, MD, MRCPsych Professor, Child and Adolescent Psychiatry Unit, Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found at https://nei.global/culture. Support: This activity is supported by an unrestricted educational grant from Sunovion. Released: December 3, 2020     CME credit expires: December 3, 2023

Dec 2020

33 min 36 sec

How can someone tell whether they are experiencing chronic levels of stress? The holidays are typically a great source of stress for most people. What are the unique challenges that we face this year in terms of the holidays during a pandemic? In this timely interview, Dr. Jennifer Love addresses these important questions, and so much more in this episode. With the release of her upcoming book, “When Crisis Strikes” she shares some powerful tips on detecting and managing chronic stress. Dr. Jennifer Love is board-certified in psychiatry, addiction psychiatry and addiction medicine, and is a Diplomate of the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She practices at a large clinic in Southern California. Dr. Love is an award-winning researcher and international speaker, interested in the interface between cultural and spiritual factors and overall mental health. Dr. Love’s work focuses on restoring life balance, brain and body health, and helping her patients improve their functionality and satisfaction in life. She considers a wide range of interventions including nutraceuticals, medication, exercise, yoga, psychotherapy, and sleep/relaxation training. Her specialties include: mood disorders, substance-use disorders, anxiety disorders, anger and irritability, behavioral addictions, co-occurring pain and opioid dependence. Dr. Love is the co-author of When Crisis Strikes: 5 Steps to Heal Your Brain, Body, and Life from Chronic Stress. Stay up to date by following @dr_author_jennifer_love on Instagram.        

Dec 2020

50 min 24 sec

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary movements of the tongue, lips, face, trunk, and extremities that occur in patients treated with dopamine receptor blocking agents (DRBAs). Patients can have symptoms that persist for months, years, or even permanently. Greater awareness about risk factors and which agents may be associated with higher likelihood of developing TD is critical to reduce the prevalence of this disorder. Understanding the most effective novel treatment approaches to TD is also important. In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the current best practices in the diagnosis, recognition, and treatment of tardive dyskinesia.  Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-TD  Learning Objectives: After completing this educational activity, you should be better able to: Identify the clinical presentation of tardive dyskinesia Implement treatment strategies for the management of tardive dyskinesia  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by a PhD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Neurocrine Continental, Inc.  Released: November 19, 2020          CME credit expires: November19, 2023

Nov 2020

41 min 6 sec

What are the most common reasons for insomnia? What is effective for treating insomnia? Can you explain sleep hygiene? In Part 2 she answers these questions and so much more! Dr. Jade Wu is a licensed clinical psychologist, sleep researcher, and host of the Savvy Psychologist podcast. She is a frequent guest on popular radio and podcast shows such as NPR, and quoted in popular press publications like New York Times, NBC News, and Huffington Post. Her current research focuses on treating sleep disorders in those with chronic illness. In the clinic, Dr. Wu uses evidence-based non-medication treatments to help people improve their sleep (and wake). Her approach is grounded in both science and compassion, so that her clients are empowered to live healthier and more fulfilled lives.  My website: www.JadeWuPhD.com Twitter: @JadeWuPhD Resources can be found on her website under the "Resources" tab.

Nov 2020

24 min 7 sec

Join us for this important extended Q&A session with psychiatric nurse practitioner; Deb York, in which she answers your most pressing questions from her presentation on early life childhood adversity.

Nov 2020

14 min 45 sec

Join us for a fascinating extended Q&A with Dr. William Sauve’ where he addresses your unanswered questions from his presentation on the mental health consequences of COVID-19.

Nov 2020

21 min 55 sec

In this episode, listen in for an extended Q&A session with Dr. Jeffrey Strawn as he answers your most pressing questions from his presentation on treating refractory anxiety disorders.

Nov 2020

18 min 55 sec

In this exciting extended Q&A session, Dr. James Knoll addresses your unanswered questions from his presentation on Mass Shootings.

Nov 2020

15 min 27 sec

How do we know how much sleep we actually need? Are devices like the FitBit accurate at tracking what stage of sleep we’re in, according to heart rate? How does substance abuse contribute to nightmares? In this episode of the NEI Podcast, psychiatrist and sleep researcher, Dr. Jade Wu answers these questions and so much more! Learn about her cutting-edge research in Part 1 of this episode. Dr. Jade Wu is a licensed clinical psychologist, sleep researcher, and host of the Savvy Psychologist podcast. She is a frequent guest on popular radio and podcast shows such as NPR, and quoted in popular press publications like New York Times, NBC News, and Huffington Post. Her current research focuses on treating sleep disorders in those with chronic illness. In the clinic, Dr. Wu uses evidence-based non-medication treatments to help people improve their sleep (and wake). Her approach is grounded in both science and compassion, so that her clients are empowered to live healthier and more fulfilled lives.  My website: www.JadeWuPhD.com Twitter: @JadeWuPhD Resources can be found on her website under the "Resources" tab.

Nov 2020

25 min 15 sec

How are social media platforms being used for negativity and what can people do to protect their mental health on these platforms? How have you used Tiktok and other social media platforms to help remove the stigma associated with mental health conditions, and to make a positive impact in the adolescent population? In this episode, we interview psychiatric nurse practitioner, Dr. Sarfo Kojo on how he is using social media to create a positive impact on mental health. Dr. Kojo Sarfo, DNP, PMHNP-BC is a Ghanaian-American Psychiatric-Mental Health Nurse Practitioner, entrepreneur, and writer. He graduated from The University of West Alabama with his Associate’s Degree in Nursing and then obtained his Bachelor’s in Nursing from Western Governors University. He went on to obtain his Doctorate in Nursing Practice degree from Augusta University with a specialty in Psychiatry. He has three years of teaching experience as an adjunct faculty professor with the College of Nursing at his alma mater, Augusta University. He has a passion for treating and caring for persons with severe mental health conditions. He is also the CEO and Co-Founder of Abrantie & Signora, LLC, which is a clothing company dedicated to spreading positivity and mental health awareness for teenagers and college students. Dr. Sarfo has over 328,000 followers on TikTok. For more information on Dr. Sarfo: https://www.kojosarfo.com/ Dr. Sarfo’s Podcast: https://podcasts.apple.com/us/podcast/the-kojo-sarfo-podcast/id1477749374 Dr. Sarfo’s YouTube Channel: https://www.youtube.com/kojosarfo Dr. Sarfo’s Clothing Company: https://abrantiesignora.com/ Dr. Sarfo’s Book: https://www.amazon.com/You-Already-Won-Education-Awareness/dp/1692141805/ref=sr_1_1?dchild=1&keywords=dr.+kojo+sarfo&qid=1603218480&sr=8-1  

Oct 2020

38 min 42 sec

What is an ecological momentary assessment? How are ecological momentary interventions powerful and helpful in a clinical research setting? Learn more about how digital technology, smart phone applications, electronic surveys, and wearable devices can help in both the clinical research and the clinical treatment arena. In this fascinating interview with Dr. Katherine Houghton, she answers your most pressing questions about applying digital technology to capture real-world/real-time data, and to help patients at the most critical times. Katherine Houghton, Ph.D. is fascinated by the intersection of technology and psychology. She is actively engaged in designing and testing systems to facilitate positive behavior change in a variety of populations. She co-founded ilumivu in 2009 (ilumivu.com) to provide software systems to researchers and clinicians to capture human data and deliver just-in-time interventions. Ilumivu's first software service was for parents of children with autism to track symptom change and treatment use in an online HIPAA compliant, sharable platform. Since then ilumivu has provided web, mobile and wearable systems to researchers and clinicians working with a wide range of populations including substance abuse, suicide, anxiety and depression. They are committed to finding innovative and effective ways to use everyday technology to improve the daily life experience of the millions of people who suffer with mental health issues. *Optional*Kat is also very engaged in local environmental activism bringing Community Rights and the Rights of Nature to the City of Asheville through a nonprofit she co-founded, Community Roots (cmroots.com). She also leads wilderness Rites of Passage ceremonies to help people through challenging times. Resources: Ilumivu website: https://ilumivu.com/ Ilumivu Twitter: https://twitter.com/ilumivuTweets Kat's LinkedIn: https://www.linkedin.com/in/kathoughton/ Website to Kat's non-profit, Community Roots: https://www.cmroots.com/   Need to fulfill your CME credits? Join us virtually at NEI Max! and earn up to 28.75 CME credits. Check out with promo code PODCAST09 to get 10% off.  

Oct 2020

35 min 43 sec

Opioid addiction, abuse, and overdose have all grown to epidemic proportions in the United States as well as worldwide in recent years—such information is no longer up for debate. With an estimated 400,000 persons using illicit opiates each month, and another 4 million reporting use of prescription pain relievers for nonmedical purposes, in the United States alone, the debate now surrounds how best to treat those individuals suffering from opioid use disorder (OUD). In the past few years, there has been growing evidence for the efficacy of medication assisted therapy (MAT) for the treatment of OUD. However, there are still many challenges. Questions arise such as: What sort of training does a prescriber need to undertake in order to be able to prescribe medications for the treatment of OUD and how is this a barrier to treatment? How are the billing procedures for MAT challenging for clinicians who are prescribing? In this CME NEI Podcast, Dr. Larissa Mooney answers these questions and more on MAT for OUD. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Describe the challenges to treating opioid use disorder (OUD) with medication assisted therapy (MAT) Explore treatments designed to optimize cessation of opioid addiction Discuss legal barriers and insurance barriers to treatment of OUD  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as “providers of formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Faculty Interviewer / Author Larissa J. Mooney, MD Associate Clinical Professor, Department of Psychiatry and Biobehavioral Sciences; Director, Addiction Medicine Clinic; University of California, Los Angeles Semel Institute for Neuroscience and Human Behavior, Los Angeles, CAChief, Substance Use Disorders Clinic, VA Greater Los Angeles Healthcare System, Los Angeles, CA No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Alkermes.  Released: Sept 30, 2020          CME credit expires: Sept 30, 2023   Need to fulfill your CME credits? Join us virtually at NEI Max! and earn up to 28.75 CME credits. Check out with promo code PODCAST09 to get 10% off.

Sep 2020

31 min 9 sec

September is National Recovery Month! In this invigorating interview with addiction expert, Dr. Nzinga Harrison, we discuss the need for removing the stigma and misconceptions surrounding the topic of addiction, and how to apply treatment strategies focused on understanding compassion, and evidence-based scientific research. When it comes to addiction, there are many questions. What does it mean to say that someone is in recovery? What are some behavioral addictions that most people don’t think about? Are there such things as healthy addictions? In this episode, Dr. Harrison shares a refreshing and novel perspective on the topics of addiction and recovery. A well-respected physician and educator, Dr. Harrison is the host of the In Recovery weekly podcast by Lemonada Media, she engages a large audience on all things addiction with the goal of leading with compassion, evidence and reducing stigma.   She is Chief Medical Officer and Co-Founder of  Eleanor Health, an innovative company who provides comprehensive, longitudinal outpatient care for individuals experiencing opioid and other substance use disorders. She earned her Bachelor’s degree in Biology with Spanish and Chemistry minors at Howard University, completed medical school at the University of Pennsylvania School of Medicine and General Psychiatry Residency at Emory University.   She is Board-Certified in both Adult General Psychiatry and Addiction Medicine and has spent her career treating individuals with Serious Persistent Mental Illness and Addictive Diseases.  Currently, she holds adjunct faculty appointments at the Morehouse School of Medicine Department of Psychiatry is Co-Founder of Physicians for Criminal Justice Reform, Inc. and Campaign Psychiatrist for Let’s Get Mentally Fit, a public education and stigma-reduction campaign.   Resources: Dr. Nzinga Harrison’s In Recovery Podcast: https://www.lemonadamedia.com/show/in-recovery/ Eleanor Health: https://www.eleanorhealth.com/  

Sep 2020

44 min 39 sec

When it comes to serious mental illness (SMI), mental health professionals work hard to help remove the associated negative stigma, and to educate patients and caregivers to help them thrive. In this episode, we interview two clinical experts who are part of an interdisciplinary team at the APA/SMI Advisor program. This joint initiative between the American Psychiatric Association and the Substance Abuse and Mental Health Services Administration, or SAMSHA is an innovative clinical support program for clinicians, caregivers, and patients with serious mental illness.  In this episode, we discuss the topic of serious mental illness with two mental health experts, Dr. Donna Rolin and Dr. Joseph Ventura. We also discuss their upcoming joint-presentation at this year’s APNA, on the importance of incorporating the Basic Psychiatric Rating Scale (BPRS) into practice.   Donna Rolin, Ph.D. is Clinical Associate Professor and the Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Texas with 23 years of experience in psychiatric nursing. She is co-leading inter-disciplinary graduate training initiatives with Schools of Nursing, Medicine, Educational Psychology, Social Work, and Pharmacy with funding from the Health Resources and Services Administration and the Texas Higher Education Coordinating Board aiming to expand a culturally diverse workforce for underserved populations. She serves as the Co-Director of the Institute for Domestic Violence and Sexual Assault (IDVSA), working alongside Schools of Social Work, Law and Bureau of Business Research. Dr. Rolin’s current research focuses on wellness self-management for mental health promotion and the integration of telepresence robots in healthcare education. Dr. Rolin serves on the national Board of Directors of the American Psychiatric Nurses Association and the local Board of the Directors of the Psychiatric Advanced Practice Nurses of Austin. Dr. Rolin continues her clinical practice as a Psychiatric Advanced Practice Registered Nurse with a community-based group working with underserved patients with serious mental illnesses (SMI), neurocognitive disorders, and intellectual disabilities in outpatient, long term care, telepsychiatry, and inpatient psychiatric facilities. She acts as the SMI Nursing Expert on the American Psychiatric Association’s Clinical Support Services for SMI (CSS-SMI) Clinical Expert Team. Joseph Ventura, Ph.D. is a Clinical Psychologist and Research Scientist with expertise in the assessment and treatment of individuals with serious mental illness. Dr. Ventura is the Director of Cognitive Training and Diagnosis and Symptom Assessment for the UCLA Aftercare Program. His areas of expertise include cognitive remediation, assessment of neurocognitive functioning, psychiatric diagnosis, symptom assessment, recovery from mental illness, and evaluation of functional outcomes in the early phase of schizophrenia. Dr. Ventura has led research funded by several agencies most notably the National Institute of Mental Health (NIMH) and the Brain and Behavior Foundation (formerly NARSAD). His research has concentrated on stressful life events, positive and negative symptoms, neurocognition, social cognition, cognitive training, and predictors of course and functional outcome. Dr. Ventura has played a major role in the development and publication of methods for standardizing diagnostic and symptom assessment training and for ongoing quality assurance. His recent work focuses on clinical correlates of the core features of serious mental illness, dimensions of social cognition, inflammatory biomarkers, the development of interview-based assessments of cognitive functioning, and factors that are associated with recovery from serious mental illness. Recently, he was awarded a US Fulbright Scholar Grant to develop a program promoting early assessment, identification, and prevention of mental illness in clinical high-risk populations in North Africa. Dr. Ventura has published widely in peer-reviewed journals, lectured extensively, and conducted numerous training workshops both nationally and internationally. UCLA Aftercare Program: The UCLA Aftercare Program (brochure attached) is a joint clinical and research program located in the UCLA Department of Psychiatry specializing in the treatment of people who are in the early phase of schizophrenia or a related psychotic disorder. For over 30 years, and through NIMH and industry funding, our Aftercare treatment team has been providing comprehensive services to schizophrenia patients most of whom are transitional age youth (late teens or early twenties). However, we can serve patients from age 18 to 45. Our primary treatment aim is to assist patients with symptomatic and functional recovery after experiencing a first psychotic episode or who are within 2 years of the first onset of psychotic symptoms.  The Aftercare program provides a comprehensive set of treatment services to eligible patients including regular visits with a psychiatrist, anti-psychotic medication (second generation), case management, various forms of psychosocial interventions including group and individual therapy, a cognitive training program that is in some cases boosted by an aerobic exercise program, family education and support, and transportation to UCLA. Our clinic psychiatrists are Laurie Casaus, M.D. and Margaret Distler, M.D. Additional Aftercare services include, supported employment and supported education programs, family therapy, and providing research updates to family members. We can provide all of these services for up to two years at no cost to the patient or family because we are funded.   The Aftercare clinic is headed by members of the UCLA Department of Psychiatry, Keith Nuechterlein, Ph.D., Kenneth Subotnik, Ph.D., Luana Turner, PsyD., Joseph Ventura, Ph.D, who have been providing these services through the Aftercare Program for many years to early course patients. Rebecca Zornitsky, MSc. is our Community Liaison Specialist along with Taylor Jester and Elaine Clarke. APA/SMI Adviser Site & Resources: https://smiadviser.org/ Clozapine Center of Excellence: https://smiadviser.org/about/clozapine Long-Acting Injectable (LAI) Antipsychotics Center of Excellence: https://smiadviser.org/about/lai How to download SMI Adviser App: Apple: https://apps.apple.com/us/app/smi-adviser/id1473024646 Google: https://play.google.com/store/apps/details?id=org.smiadviser&hl=es_PE How to download My Mental Health Crisis Plan (Psychiatric Advance Directive [PAD]) App Apple: https://apps.apple.com/us/app/my-mental-health-crisis-plan/id1497373282 Google: https://play.google.com/store/apps/details?id=org.smiadviser.apa&hl=en_US APNA Annual Meeting Presentation on Brief Psychiatric Rating Scale (BPRS) Annual Meeting 9/30 – 10/4/2020 (Virtual) https://www.apna.org/i4a/pages/index.cfm?pageid=3467 Presentation on BPRS – Dr. Joseph Ventura & Dr. Donna Rolin Thursday, 10/1 @5pm ET https://www.apna.org/i4a/pages/index.cfm?pageID=4595 2034: Advanced Practice 5:00pm ET - 5:45pm ET Using the Brief Psychiatric Rating Scale (BPRS) as a Symptom Assessment Tool in Measurement-Based Care – RN, APRN This interactive presentation teaches participants to rate psychiatric symptoms using a structured interview, the Brief Psychiatric Rating Scale. The goal is to build and/or expand assessment skills for rating initial symptom severity and for monitoring symptom change over time to improve quality of treatment within a measurement-based care approach.  Abstract Presenters: Joseph Ventura, PhD; Donna Rolin, PhD, APRN, PMHCNS-BC, PMHNP-BC  

Sep 2020

32 min 20 sec

Autism Spectrum Disorder (ASD) is highly comorbid with other psychiatric disorders, including attention deficit hyperactivity disorder (ADHD). Unfortunately, there may be many overlapping symptoms between ASD and ADHD that make it difficult to distinguish between these disorders. In this fascinating episode, Dr. David Goodman examines the history of autism, Asperger’s disorder, and how to differentiate between overlapping symptoms for ADHD. He also addresses how to treat these disorders concurrently. Dr. David W. Goodman is an assistant professor in the department of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore, and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD. His interests include adult ADHD, associated mood/anxiety/substance use disorders, and complex psychopharmacology.

Aug 2020

24 min 35 sec

What specific issues do female nurse practitioners, or physicians treating mental health face in the workplace? What are some of the work-life issues that women face, when it comes to balancing a career in medicine with family? What are the research findings on sexual harassment toward women in the mental health profession? In this important episode, Dr. Christina Girgis addresses these questions, and more! Dr. Christina Girgis is a psychiatrist in the Hines, Illinois area, certified by both the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She is currently the Medical Director of the Consultation-Liaison Psychiatry Service at Edward Hines, Jr. VA Hospital and the Associate Training Director of the Psychiatry Residency Program at Loyola University Medical Center. She is also the founder of Psychiatry Network, and several other professional Facebook groups. For more information please click on the link below: https://www.facebook.com/groups/psychnetwork/

Aug 2020

47 min 13 sec